Research programme: antigen processing-independent epitopes - Apitope Technology
Alternative Names: API F-VIII; ATX-F8-17; ATX-GD-450; ATX-GD-459; ATX-UV1; ATX-UV2; iATX Factor VIIILatest Information Update: 28 Aug 2024
At a glance
- Originator Apitope Technology
- Class Peptides
- Mechanism of Action Immunomodulators; Thyrotropin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Graves' disease; Haemophilia A; Uveitis
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Uveitis in United Kingdom (Parenteral)
- 19 Aug 2022 Research development in Uveitis is ongoing in United Kingdom (Parenteral) (Worg Pharmaceuticals pipeline, August 2022)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in United Kingdom (Parenteral)